Clinical Trial Support
The K-CONNECT Platform actively fosters strategic collaborations with leading investigators at medical centers, hospitals, and biopharmaceutical companies across the Asia-Pacific region.
We invite researchers and clinical leaders to join us in advancing data-driven, patient-centered cancer care—by leveraging cutting-edge technologies such as ctDNA, MRD, and multi-omic profiling in real-world clinical trials.
We’d love to hear your questions! Please feel free to submit any inquiries you may have about K-TRACK.
ctDNA Monitoring to Predict the Efficacy of TNT for Rectal Cancer
Key finding:
This is a prospective observational study, in collaboration with 3 hospitals (175 Military Hospital, Nguyen Tri Phuong Hospital, and 108 Military Central Hospital), plans to recruit 100 patients with stage II-III rectal cancer and indicated for total neoadjuvant therapy. K-TRACK assay will use to evaluate value of ctDNA in Predict the Efficacy of TNT for Rectal Cancer.
Investigate the Prognostic and Predictive Value of ctDNA During Neoadjuvant Chemotherapy for Breast Cancer
Key finding:
This prospective and observational study, in collaboration with University Medical Center HCMC, plans to recruit 75 patients with stage II-III HER+/Triple Negative Breast cancer and indicated for neoadjuvant chemotherapy. K-TRACK assay will use aim to determine the detection rate and change of ctDNA in blood samples of cancer patients before, during and after neoadjuvant treatment.
